Literature DB >> 29752991

Cerebrolysin attenuates hyperalgesia, photophobia, and neuroinflammation in a nitroglycerin-induced migraine model in rats.

Javad Mahmoudi1, Gisou Mohaddes1, Marjan Erfani2, Saeed Sadigh-Eteghad1, Pouran Karimi1, Mojgan Rajabi3, Siamak Reyhani-Rad4, Fereshteh Farajdokht5.   

Abstract

Chronic migraine dramatically affects the quality of life in the migraineurs. This study examined the effect of chronic cerebrolysin (CBL) treatment on the migraine-associated symptoms in a rat model of migraine. Experiments were carried out on 8 weeks, male Wistar rats. Chronic migraine was modeled by injection (10 mg/kg, i.p) of nitroglycerin (NTG) on days 3, 5, 7, and 9. CBL (2.5 and 5 ml/kg, i.p.) was injected every day for 10 days. Mechanical and thermal withdrawal thresholds of the hind paw were examined by von Frey hairs and hot plate, respectively. Head grooming behavior was evaluated one hour following injection of NTG. Light-aversive behaviors were determined in the modified elevated plus-maze (EPM) on even days and in the light/dark box on odd days. After behavioral experiments, blood concentrations of calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), tumor necrosis factor-a (TNF-α), and interleukin-1β (IL-1β) were assessed by rat specific enzyme-linked immunosorbent assay (ELISA) kits. Our results indicated that NTG significantly increased migraine-related behavioral and molecular symptoms in the animals, whereas CBL treatment markedly reduced mechanical and thermal hyperalgesia, head grooming, and light-aversive behaviors induced by NTG. Also, blood levels of CGRP, PACAP, and pro-inflammatory cytokines (TNF-α and IL-1β) significantly decreased by CBL administration. Chronic CBL treatment showed antinociceptive and light-aversive reducing effects in the NTG-induced animal model of chronic migraine and may represent a valuable therapy for those suffering from migraine.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CGRP; Cerebrolysin; Head grooming; Hyperalgesia; Neuroinflammation; PACAP

Mesh:

Substances:

Year:  2018        PMID: 29752991     DOI: 10.1016/j.brainresbull.2018.05.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  Investigating Migraine-Like Behavior Using Light Aversion in Mice.

Authors:  Mengya Wang; Bianca N Mason; Levi P Sowers; Adisa Kuburas; Brandon J Rea; Andrew F Russo
Journal:  J Vis Exp       Date:  2021-08-11       Impact factor: 1.424

2.  Does fructose have a protective role on migraine?-experimental evidence in a rat model of metabolic syndrome under omega-3 supplementation.

Authors:  Isadora R Barbosa; Gabriela da Cunha; Rodrigo B M Silva; Raquel D S Freitas; Ana P A Dagnino; Maria M Campos
Journal:  Ann Transl Med       Date:  2022-04

3.  Gut Microbiota Dysbiosis Enhances Migraine-Like Pain Via TNFα Upregulation.

Authors:  Yuanyuan Tang; Sufang Liu; Hui Shu; Lora Yanagisawa; Feng Tao
Journal:  Mol Neurobiol       Date:  2019-08-04       Impact factor: 5.590

4.  Microglia P2X4R-BDNF signalling contributes to central sensitization in a recurrent nitroglycerin-induced chronic migraine model.

Authors:  Ting Long; Wei He; Qi Pan; Shanshan Zhang; Dunke Zhang; Guangcheng Qin; Lixue Chen; Jiying Zhou
Journal:  J Headache Pain       Date:  2020-01-14       Impact factor: 7.277

5.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

Review 6.  The neurobiology of pain and facial movements in rodents: Clinical applications and current research.

Authors:  Adriana Domínguez-Oliva; Daniel Mota-Rojas; Ismael Hernández-Avalos; Patricia Mora-Medina; Adriana Olmos-Hernández; Antonio Verduzco-Mendoza; Alejandro Casas-Alvarado; Alexandra L Whittaker
Journal:  Front Vet Sci       Date:  2022-09-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.